Tools for auto-segmentation in radiotherapy are widely available, but guidelines for clinical implementation are missing. The goal was to develop a workflow for performance evaluation of three commercial auto-segmentation tools to select one candidate for clinical implementation. One hundred patients with six treatment sites (brain, head-and-neck, thorax, abdomen, and pelvis) were included. Three sets of AI-based contours for organs-at-risk (OAR) generated by three software tools and manually drawn expert contours were blindly rated for contouring accuracy. The dice similarity coefficient (DSC), the Hausdorff distance, and a dose/volume evaluation based on the recalculation of the original treatment plan were assessed. Statistically significant differences were tested using the Kruskal-Wallis test and the post-hoc Dunn Test with Bonferroni correction. The mean DSC scores compared to expert contours for all OARs combined were 0.80 ± 0.10, 0.75 ± 0.10, and 0.74 ± 0.11 for the three software tools. Physicians' rating identified equivalent or superior performance of some AI-based contours in head (eye, lens, optic nerve, brain, chiasm), thorax (e.g., heart and lungs), and pelvis and abdomen (e.g., kidney, femoral head) compared to manual contours. For some OARs, the AI models provided results requiring only minor corrections. Bowel-bag and stomach were not fit for direct use. During the interdisciplinary discussion, the physicians' rating was considered the most relevant. A comprehensive method for evaluation and clinical implementation of commercially available auto-segmentation software was developed. The in-depth analysis yielded clear instructions for clinical use within the radiotherapy department.
Aim: The aim of this study was to assess the effects of including somatostatin receptor agonist (SSTR) PET imaging in meningioma radiotherapy planning by means of changes in inter-observer variability (IOV). Further, the possibility of using threshold-based delineation approaches for semiautomatic tumor volume definition was assessed. Patients and Methods: Sixteen patients with meningioma undergoing fractionated radiotherapy were delineated by five radiation oncologists. IOV was calculated by comparing each delineation to a consensus delineation, based on the simultaneous truth and performance level estimation (STAPLE) algorithm. The consensus delineation was used to adapt a threshold-based delineation, based on a maximization of the mean Dice coefficient. To test the threshold-based approach, seven patients with SSTR-positive meningioma were additionally evaluated as a validation group. Results: The average Dice coefficients for delineations based on MRI alone was 0.84 ± 0.12. For delineation based on MRI + PET, a significantly higher dice coefficient of 0.87 ± 0.08 was found (p < 0.001). The Hausdorff distance decreased from 10.96 ± 11.98 mm to 8.83 ± 12.21 mm (p < 0.001) when adding PET for the lesion delineation. The best threshold value for a threshold-based delineation was found to be 14.0% of the SUVmax, with an average Dice coefficient of 0.50 ± 0.19 compared to the consensus delineation. In the validation cohort, a Dice coefficient of 0.56 ± 0.29 and a Hausdorff coefficient of 27.15 ± 21.54 mm were found for the threshold-based approach. Conclusions: SSTR-PET added to standard imaging with CT and MRI reduces the IOV in radiotherapy planning for patients with meningioma. When using a threshold-based approach for PET-based delineation of meningioma, a relatively low threshold of 14.0% of the SUVmax was found to provide the best agreement with a consensus delineation.
Summary: Purpose: Technical improvements over the last few years regarding administration of locally ablative radiotherapy to oligometastatic (OMD) and oligoprogressive (OPD) disease in breast cancer has created increased interest. This article gives an overview of the current situation from the perspective of a radiation oncologist. Findings: Stereotactic radiotherapy (SBRT) is the most common form for applying ablative radiotherapy doses in metastases-directed therapy (MDT) to oligometastatic or oligoprogressive sites in breast cancer. To the present day, the literature mainly consists of retrospective or nonrandomized trials with mixed results. Nevertheless, there is a growing number of prospective randomized and phase III trials which will soon give us more data in this promising field. Conclusion: With growing interest in treating patients with OMD or OPD in a curative intent, locally ablative therapies are gaining more importance. SBRT is a feasible modality with very good results in local disease control and a low toxicity profile and therefore a promising option for treating breast cancer patients with OMD or OPD. Nevertheless, current data does not yet back the routine use, with more prospective data expected soon. Until then, treatment options for those patients should be discussed individually.
13 October 2016 in Geburtshilfe und Frauenheilkunde
Sporadic ovarian cancer has the highest relative mortality among gynecological cancers. As early symptoms are nonspecific 75% of patients are diagnosed at an advanced stage leading to poor overall survival. To improve patient's outcome targeted therapy strategies are highly demanded. Thus, in search of new biomarkers for personalized ovarian cancer therapy, we recently identified a gene encoding a specific neuronal calcium sensor (NCS) protein. The NCS-family is mainly known to be involved in calcium-signaling on membranes and functions as calcium dependent molecular switches. Chip-based mRNA expression of the candidate was significantly associated with patient outcome which was confirmed by qPCR experiments and by validation studies using independent publicly available mRNA microarray data sets (http://kmplot.com). Multivariable Cox regression analyses confirmed the candidate as independent marker. We then explored the candidate's protein expression in tissue micro arrays, which confirmed that high candidate expression was significantly associated with favorable patient outcome. Most interestingly, we also found specific protein expression in germinal centers of tonsils, indicating a role of the candidate in immune response. Next to its tumor biological role regarding cellular apoptosis, proliferation, and migration in human ovarian cancer cells, we intend to investigate its potential as a predictive marker for new immuno-based therapies, as immunotherapy offers a novel and promising therapeutic strategy for treating ovarian tumors. Since these biomarkers distinguish between patients who will most probably benefit from such new therapy approaches and those who will not they may help to assign the appropriate therapy approach to the respective patient subgroup.
Purpose: Male breast cancer (maleBC) is an orphan disease. Aside from age, risk factors include genetic mutations and conditions like Klinefelter syndrome or other reasons of hypogonadism. Treatment is based on standards in women, but biological differences may exist, with maleBC exhibiting higher rates of hormone-receptor expression. Limiting data exists regarding the rate of low/ultralow HER2 expression, a predictive biomarker for the antibody–drug conjugate (ADC) trastuzumab deruxtecan (T-DXd) in HER2-negative disease in women. Materials and Methods: We conducted a retrospective single-center analysis of clinicopathological features of maleBC at a tertiary cancer center. We identified a cohort of 57 maleBC patients, described demographic, pathological, prognostic and surgical and systemic treatment data and evaluated frequencies of low and ultralow HER2 expression. Results: The mean age was 64.3 (SE ± 1.79) years; 94.7% (n = 54) of patients presented with early/nonmetastatic breast cancer and 40.7% (22 of 54) of patients exhibited nodal involvement. Most patients (92.6%, 50 of 54 patients) had luminal disease and approximately one third of patients received chemotherapy. Endocrine therapy was administered in 87.7% (n = 50/57) of cases. For 52 of the patients included, full receptor status data including HER2 IHC scoring and/or histological specimens were available. IHC slides of tumor specimens from 24 patients with either historically reported “HER2 negative” or “HER2 0” expression were available for reassessment; 79.2% (n = 19 of 24) of these tumors exhibited either HER2-low or -ultralow expression. In the whole cohort, rates of HER2-low and -ultralow expression were 75.0% (39 of 52) and 5.8% (3 of 52 patients), respectively. The median follow-up was 7 years. Six deaths occurred in the total population (n = 57). The median event-free survival (EFS) was 8.39 years (95% CI 7.36–11.35). No statistically significant associations were observed between HER2 expression categories and clinicopathological variables including grade, ER status, nodal status, genetic variant status, age, Ki67 index, or overall survival events. Conclusions: In this cohort of maleBC patients, high rates of combined HER2-low and -ultralow expression were observed upon reassessment of tumors with historically negative HER2 status, shedding light on potential ADC eligibility in male breast cancer.